Grantham, Mayo, Van Otterloo & Co (GMO)
ADMS

Grantham, Mayo, Van Otterloo & Co (GMO)’s Adamas Pharmaceuticals ADMS Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-39,400
Closed -$189K – 890
2021
Q1 		$189K Buy
+39,400
New +$206K ﹤0.01% 824

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s ADMS Position: Q2 2021 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Adamas Pharmaceuticals (ADMS) in Q2 2021, closing a stake of 39,400 shares — an estimated $189K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in ADMS in Q1 2021 and held it in 1 quarter. The position peaked at $189K in Q1 2021. 67 funds tracked by Wall St. Rank hold ADMS as of Q2 2021.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Adamas Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 39,400 Adamas Pharmaceuticals shares in Q2 2021, an estimated $189K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Adamas Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Adamas Pharmaceuticals position peaked at $189K in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q2 2021.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2021, filed 12 Aug 2021.